Clinical Trial Update: A Clinical Study of NAD in the Treatment of Immune Thrombocytopenia [Phase 1, Phase 2]

View source ↗

Summary

Ongoing Phase 1/2 clinical trial in China evaluating nicotinamide adenine dinucleotide (NAD) for immune thrombocytopenia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Immune Thrombocytopenia

Drugs mentioned

• NAD+ (nicotinamide adenine dinucleotide)

Snippet

Sponsor: Institute of Hematology & Blood Diseases Hospital, China | Conditions: Immune Thrombocytopenia, Treatment | Phase 1, Phase 2 | Status: RECRUITING